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Abstract. 
Although current treatment can improve the complete remission rate of T-cell acute lym-
phoblastic leukemia (T-ALL), approximately half of the patients relapse within the first 2 years 
and have poor prognosis. Nelarabine is a novel purine nucleoside analog, and has been proven 
efficacious against both refractory and relapsed T-ALL. However, its adverse neurological ef-
fects are also well recognized. We report a 37-year-old patient with relapsed T-ALL who de-
veloped weakness and paresthesia over the lower limbs bilaterally, with difficulty urinating, 
after three cycles of nelarabine were administered as bridging therapy to allogeneic stem cell 
transplantation. The patient’s symptoms were irreversible and progressed to complete paraple-
gia in a week, and he expired due to disease progression after two months. Notwithstanding the 
proven efficacy of nelarabine, the drug’s potentially lethal neurological toxicity should always 
be carefully monitored during therapy. 
 














nelarabine 可能產生的毒性，並在使用 nelarabine 治療時，提高警覺，小心監測病人的神
經學症狀。 
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 INTRODUCTION 
In the last 20 years, the treatment outcomes for pa-
tients with T-cell acute lymphoblastic leukemia 
(T-ALL) have improved significantly. T-ALL patients 
have achieved a complete remission rate of approxi-
mately 90%, with a 50% five-year overall survival 
rate [1]. However, prognosis is still poor for patients 
whose first line induction therapy failed, or suffered 
relapse. Thus, it is critical that an effective salvage 
therapy be developed to more successfully manage 
T-ALL, and further reduce patient mortality. 
Nelarabine (Arranon®), a synthesized purine nu-
cleoside analog and pro-drug of arabinosylguanine 
nucleotide triphosphate (araGTP), results in the inhi-
bition of DNA synthesis and cytotoxicity. The efficacy 
of nelarabine has been proven in several phase I and II 
trials [2-4], and it was approved by the FDA for 
T-ALL and T-cell lymphoblastic lymphoma for pa-
tients whose disease dose was unresponsive to or re-
lapse following treatment with at least two chemo-
therapy regimens since 2005. Although no incidents of 
hematological toxicity have surfaced, neurologically 
adverse events accompanying nelarabine use have 
been reported, such as peripheral neuropathy, seizure, 
and hallucination. We would like to report a patient 
with T-ALL who received nelarabine who thereafter 
developed progressive ascending paralysis. 
 
CASE REPORT 
A 37-year-old man was diagnosed as having pre-
cursor T-cell lymphoblastic leukemia (initial WBC: 
378 x 103/μL, blast cells: 93%, flow cytometry: CD2+, 
cCD3+, CD7+, MPO-, 46~47,XY,+10[9], +mar[3] 
[cp10] / 46,XY[10]). He had no CNS involvement 
(negative lumbar puncture finding), and received eight 
chemotherapy cycles of Hyper CVAD (cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone 
alternative with methotrexate and cytarabine) (Octo-
ber 2010 to May 2011) with complete remission. He 
then underwent maintenance therapy with POMP 
(6-mercaptopurine, vincristine, methotrexate, and 
prednisone). Unfortunately, his disease relapsed in 
June 2012. The patient subsequently underwent a 
chemotherapy series consisting of Hyper CVAD, 
ID-FLAG (idarubicin, fludarabine, cytarabine, and 
G-CSF), without remission. Subsequently, one cycle 
of nelarabine (1.5g/m2/day on day 1, 3, and 5) was 
administered, and complete remission again was 
achieved. During the period of preparation for alloge-
neic stem cell transplantation, the patient received two 
additional cycles of nelarabine (650mg/m2/day for five 
days) in combination with cyclophosphamide and 
etoposide as a bridging therapy. 
Two weeks after the last cycle of chemotherapy, 
the patient developed a gradual onset of weakness and 
paresthesia over his bilateral legs and difficulty in 
urination that requiring urethral catheterization. Upon 
further patient examination, the plantar response of 
both extensor tendons and the deep tendon reflexes of 
his lower extremities were absent. His neurological 
symptoms progressively worsened to the point of 
complete numbness over the bilateral lower limbs 
with an inability to stand, all manifesting over a peri-
od of one week. Cerebrospinal fluid analysis showed 
no leukemia involvement or central nervous system 
infection. Spinal magnetic resonance imaging (MRI) 
revealed minimal scoliosis and only mild herniations 
of the L1-2 and L3-4 discs, which were not compati-
ble with clinical presentations (Figure 1). A nerve 
conduction study (NCS) showed that the amplitude of 
compound muscle action potentials (CMAPs) of the 
bilateral common peroneal and tibial nerves were re-
duced, which was compatible with lower limb moder-
ate to severe sensorimotor polyneuropathy. A prelimi-
nary diagnosis of nelarabine-related neuropathy was  
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Figure 1. Mild herniations of L1-2, and L3-4 disc in 
magnetic resonance imaging study 
 
 
made, and we discontinued chemotherapy; additional-
ly, a hold was applied to the patient’s stem cell trans-
plantation due to his poor performance status. The 
neurological defects progressed and were irreversible, 
and the patient expired due to leukemia progression 
after two months.  
 
DISCUSSION 
Nelarabine is a novel purine analogue, and several 
phase I/II trials have identified the drug as a promising 
agent for patients with T-ALL either as a single agent 
or in combination with other cytotoxic drugs. Alt-
hough significant hematologic toxicity has not been 
observed, severe neurotoxicities, sometimes even fatal, 
have been reported.  
Kurtzberg et al. reported a phase I trial of 
nelarabine for refractory hematologic malignancies in 
which various doses (5, 10, 20, 40, 60, 75, and 90 
mg/kg/d, for 5 consecutive days) of nelarabine were 
administered [2]. Neurologic events attributable to 
nelarabine were observed in 67 (72%) of 93 patients 
enrolled into the study. In 94% of patients, the onset of 
symptoms was typically within 12 days of the start of 
drug administration of the first treatment course. 
Transient somnolence, malaise, and fatigue beginning 
6 to 8 days after the initiation of drug therapy were 
most frequently reported, particularly in adults. The 
data revealed the development of cumulative neuro-
toxicity in the form of hypoesthesias, paresthesias, or 
peripheral neuropathies in a total of 11 patients, all 
treated at the higher dose levels (1.2 g/m2; 30 and 60 
mg/kg). Gokbuget et al. reported a single-arm phase II 
study conducted in adults with relapsed/refractory 
T-ALL or lymphoma (1.5 g/m2/d, on days 1, 3, and 5) 
[5]. In that study, 16% of all patients experienced 
neurotoxicities, and 7% of the patients reached grade 
III or IV. In one patient, treatment had to be stopped 
because of a Guillain-Barre’-like syndrome presenting 
with tetraparesis, hallucinations, and reduced vigi-
lance, which developed at day 3 of the first cycle. The 
symptoms improved slowly after withdrawal. Recently, 
Hartz et al. had reported a T-ALL patient who devel-
oped spinal cord necrosis following nelarabine treat-
ment with evolutional changes observed through spi-
nal MRI [6]. 
Several nucleoside analogs used as front-line 
therapy for patients with hematological malignancies 
induce dose-limiting adverse effects. The neurotoxici-
ties associated with nelarabine are similar to those 
observed with other purine analogs, such as cytarabine. 
To date, the mechanism of purine analog-induced 
neurotoxicity is still not fully understood. Kurtzberg et 
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 al. reported that there is no increased correlation be-
tween neurotoxicity and advanced age, prior 
high-dose cytarabine therapy, prior intrathecal therapy, 
prior CNS irradiation, prior vincristine therapy or vin-
cristine-associated peripheral neuropathy, or history of 
leukemic cells in the cerebral spinal fluid [2]. Thus, 
the administered dosage level probably is the most 
important predictive factor for adverse neurological 
events.  
In our case, the patient’s neurological defects were 
not secondary to tumor involvement according to MRI 
imaging and CSF study results. The use of nelarabine 
may be strongly associated with the resulting neuro-
logical defect considering the timing of onset of neu-
rological symptoms, coupled with the high dosage 
levels administered during our patient’s treatment. Our 
patient’s NCS findings were also consistent with ax-
onal neuropathy that frequently presented in toxic 
neuropathy secondary to chemotherapy. Many reports 
have shown that nelarabine-related neurological ad-
verse events were generally transient and reversible 
after withdrawal of the drug. However, it seems that 
our patient’s neurological defects were irreversible.  
Effective treatments are still unavailable for 
nelarabine-related neurological adverse events. Ka-
wakami et al. had reported six cases of irreversible 
neurological defects developing after haploidentical 
stem cell transplantation in patients who received 
nelarabine prior to transplantation [7]. In three patients, 
NCS findings were consist with axonal neuropathy 
which is frequently observed in toxic neuropathy 
caused by various chemotherapeutic agents. Among 
those three cases, the symptoms worsened or persisted 
despite administration of corticosteroid and intrave-
nous immunoglobulin. 
In conclusion, despite the fact that nelarabine 
demonstrates clinically significant antineoplastic ac-
tivity in highly resistant relapsed T-ALL, either in sin-
gle-drug or multidrug combination regimens, possible 
patient neurological toxicities should always be care-
fully monitored during therapy. 
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